Organization
Warsaw, Poland
6 abstracts
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.Org: Istanbul Medipol University Medical Faculty, International School of Medicine, Merck & Co., Inc., Rahway, NJ, Maria Sklodowska-Curie National Institute of Oncology,
Abstract
Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.Org: Jagiellonian University Hospital, Kraków, Poland, Kraków University Hospital, Krakow, Poland, Polish Mother's Memorial Hospital - Research Institute,
Abstract
Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts.Org: ConcertAI, Bengaluru, Karnataka, Indiana University – Purdue University Indianapolis, Labcorp Drug Development Inc., Princeton, NJ,
Abstract
ARE SEROLOGIC ABNORMALITIES MANDATORY FOR LYME DISEASE DIAGNOSIS?-DIAGNOSTIC DIFFICULTIES-Org: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Orthopaedic Surgery, Hanyang University Hospital, Seoul, Korea, Republic Of, Carolina Medical Center, Pathology Deparment, Institute of Rheumatology, Belgrade, Serbia, Physical Medicine and Rhabilitation, Belgrade, Serbia,